This research study is testing a new drug called CC-94676 for men with a type of prostate cancer called metastatic castration-resistant prostate cancer. This means the cancer has spread and doesn't respond to hormone treatments that lower testosterone. The study will check if the drug is safe and how well it works.
To join, participants need to have confirmed prostate cancer that has worsened despite hormone therapy and a good health score based on the Eastern Cooperative Oncology Group (ECOG) scale. People who have had certain treatments or have other active cancers, serious blood clots, or major health issues cannot join.
- The study involves taking the study medication and regular visits to the clinic.
- Participants will be monitored closely for any side effects or improvements.
- Compensation may be provided for time and travel related to the study.
If you meet the criteria and are interested, this study could help advance prostate cancer treatments. Always discuss with your doctor before joining a clinical trial.